




Memorandum Micro #242

To: UNC Medical Center Providers and Clinics, Housestaff, Clinical Nurse Coordinators, Department Heads and Supervisors

From:  Melissa B. Miller, PhD
Director, UNCCMC Microbiology and Molecular Microbiology Laboratories

 Herbert C. Whinna, MD, PhD
Medical Director, McLendon Clinical Laboratories

Date: February 14, 2025

Subject: Change in Testing for Vaginitis

Effective February 17, 2025, UNC Medical Center McLendon Clinical Laboratories will replace the current orders for Vaginitis Screen (LAB252) and Rapid Trichomonas Screen (LAB1380) with one test: Vaginitis Molecular Panel (LAB21315). The new test is an FDA-cleared molecular test (Xpert Xpress MVP, Cepheid) for the detection of bacterial vaginosis (BV), vulvovaginal candidiasis, and *Trichomonas vaginalis* from one vaginal swab. Swabs should only be sent from symptomatic patients ≥ 14 years old.

- The BV DNA targets include three anaerobic organisms associated with BV (i.e., *Atopobium* spp., BVAB2, Megasphaera-1). Detected organisms are not reported individually.
- The *Candida* DNA targets include a “*Candida* species” result that includes but does not differentiate *C. albicans*, *C. tropicalis*, *C. parapsilosis*, and *C. dubliniensis*. A separate DNA target is used to report *C. glabrata*/*C. krusei* due to the increased likelihood of fluconazole resistance in these species.
- Specimen collection guidance can be found on the test webpage: [Vaginitis Molecular Panel](#)

- Collection swab and transport container:



- Unacceptable specimens:
 - Sources other than vaginal
 - Samples not submitted in the Xpert Swab Specimen Collection Kit
 - Samples containing the cleaning swab (large swab) instead of the collection swab

Questions can be directed to the Microbiology Lab 984-974-1805 or Dr. Melissa Miller at Melissa.Miller@unchealth.unc.edu.